J Korean Ophthalmol Soc.  2009 Aug;50(8):1221-1225. 10.3341/jkos.2009.50.8.1221.

Effectiveness of Preoperative Intravitreal Bevacizumab Injections in Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

• Jeon GS
• Han JR
• Nam WH
• Kim HK

• KMID: 2212538
• DOI: http://doi.org/10.3341/jkos.2009.50.8.1221

Abstract

PURPOSE
To evaluate the efficacy of preoperative intravitreal bevacizumab (Avastin(R); Genetech, San Francisco, CA, USA) injections of pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). METHODS: Thirty patients (30 eyes) who underwent PPV for treatment of PDR and received a preoperative intravitreal bevacizumab injection of 1.25 mg were retrospectively analyzed. The study group (group 1, 30 patients, 30 eyes) was compared with a control group (group 2, 29 patients, 30 eyes and matched with the study group for preoperative parameters) who underwent PPV without preoperative intravitreal bevacizumab injection. RESULTS: In both groups, visual acuity improved but there was no statistical significance. Intraoperative vitreous hemorrhage occurred in 14 eyes (46.7%) from group 1 and 11 eyes (36.7%) from group 2. There was no statistical significance of intraoperative bleeding occurrence (p=0.3). Postoperative vitreous hemorrhage occurred in 4 eyes from group 1 and 14 eyes from group 2. The group 1 had a lower incidence of postoperative hemorrhage than group 2 (p=0.005). CONCLUSIONS: Preoperative intravitreal bevacizumab injection appears effective in decreasing early postoperative vitreous hemorrhage and maybe technically helpful in PPV for PDR.

Keyword

Bevacizumab (Avastin(R)); Pars Plana Vitrectomy; Proliferative diabetic retinopathy

MeSH Terms

Antibodies, Monoclonal, Humanized
Diabetic Retinopathy
Eye
Hemorrhage
Humans
Incidence
Postoperative Hemorrhage
Retrospective Studies
San Francisco
Visual Acuity
Vitrectomy
Vitreous Hemorrhage
Bevacizumab
Antibodies, Monoclonal, Humanized

Figure

• 

  Figure 1. Preoperative color fundus photography of one patient in group 1. Initial presentation shows extensive fibrovacular tractional membrane overlying the optic disc.

• 

  Figure 2. Intraoperative fundus photography of one patient in group 1. Delamination of fibrovascular membrane with vertical scissors from the retina was technically easier than by conventional vitrectomy without preoperative intravitreal bevacizumab injection.

Reference

References

1. Chen E, Park CH. Use Of Intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006; 26:699–700.

2. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36:331–5.

3. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363–72.

4. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006; 26:352–4.

5. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275–8.

6. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105:998–1003.

7. Rice TA, Michels RG. Long-term anatomic and functional results of vitrectomy for diabetic retinopathy. Am J Ophthalmol. 1980; 90:297–303.

8. Spaide RF, Fisher YL. Intravitreal bevacizumab (avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26:275–8.

9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335–42.

10. Schachat AP, Oyakawa RT, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative comp-lications. Ophthalmology. 1983; 90:522–30.

11. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984; 91:1485–9.

12. West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol. 2000; 84:822–5.

13. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007; 114:710–5.

14. Bhende M, Agraharam SG, Gopal L, et al. Ultrasound biomicro-scopy of sclerotomy sites after pars plana vitrectomy for diabetic vitreous hemorrhage. Ophthalmology. 2000; 107:1729–36.

15. Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibro-vascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: Ultrasound biomicro-scopy findings. Ophthalmology. 2004; 111:1215–21.

16. Kreiger AE. Wound complications in pars plana vitrectomy. Retina. 1993; 13:335–44.

17. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage. An ultrasound biomicro-scopy study. Ophthalmology. 2005; 112:2095–102.

18. Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008; 36:449–54.